4TEEN4 Pharmaceuticals GmbH is developing a novel approach for the diagnosis and treatment of a recently discovered disease mechanism directly linked to acute organ failure, caused by a circulating enzyme in the blood (DPP3). Procizumab is a humanized therapeutic antibody currently in clinical development at 4TEEN4. Additionally, 4TEEN4 is developing diagnostic tests for the detection of severe. click apply for full job details